Synergistic Growth Hormone Releasing Peptide Blend
Overview
CJC-1295 (without DAC) and Ipamorelin are two complementary growth hormone releasing peptides frequently studied together for their synergistic effects on pulsatile GH secretion. CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist.
The “No DAC” designation means this form lacks the Drug Affinity Complex, resulting in a shorter half-life (~30 minutes vs. ~8 days for DAC-conjugated CJC-1295). This is advantageous for research requiring controlled, pulsatile GH release patterns that more closely mimic physiological GH secretion.
The combination targets both arms of the GH axis simultaneously — GHRH receptors and ghrelin receptors — producing amplified GH release greater than either peptide alone.
Mechanism of Action
- CJC-1295 (No DAC / Mod GRF 1-29): Binds to GHRH receptors on anterior pituitary somatotrophs, directly stimulating growth hormone synthesis and secretion. Four amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala, Met27→Leu) provide enhanced resistance to DPP-IV cleavage while maintaining full receptor activity. The absence of DAC allows natural GH pulsatility.
- Ipamorelin: A selective pentapeptide ghrelin mimetic that activates GHS-R1a receptors on pituitary somatotrophs. Unique among GHRPs for its high selectivity — does not significantly affect cortisol, prolactin, or ACTH levels even at high doses (Raun et al., 1998). This makes it the cleanest GH secretagogue for research applications.
- Synergistic action: Dual-pathway stimulation produces a supra-additive GH response. GHRH receptor activation primes somatotrophs for GH synthesis while GHS-R activation triggers GH release. Together, they amplify both the amplitude and duration of GH pulses while maintaining natural pulsatile secretion patterns.
- IGF-1 elevation: Sustained GH release increases hepatic IGF-1 production, which mediates many of GH’s downstream anabolic and regenerative effects.
Pharmacokinetics
- CJC-1295 (No DAC) half-life: ~30 minutes. Peak GH release at 15-30 minutes post-administration.
- Ipamorelin half-life: ~2 hours. Peak GH release at 30-45 minutes.
- GH pulse duration: Combined administration produces GH pulses lasting 2-3 hours.
- IGF-1 elevation: Sustained increases in IGF-1 observed for 24-48 hours following pulsatile GH release.
Published Research
- Teichman et al. (2006) — Journal of Clinical Endocrinology & Metabolism: CJC-1295 produced dose-dependent, sustained increases in GH and IGF-1 levels. Mean IGF-1 levels increased 1.5-3x over baseline.
- Raun et al. (1998) — European Journal of Endocrinology: Ipamorelin selectivity profile demonstrated potent GH release with no significant effect on cortisol, prolactin, FSH, LH, or TSH — uniquely selective among GHRPs.
- Johansen et al. (1999) — European Journal of Endocrinology: Ipamorelin GH release in swine models showed dose-dependent efficacy without appetite stimulation (unlike GHRP-6).
- Ionescu & Bhatt (2006) — Pituitary: Review of GHRH analogs and GHS synergy in GH axis stimulation.
- Nass et al. (2008) — Annals of Internal Medicine: Effects of GH secretagogue (MK-677) on body composition, demonstrating the potential of GHS receptor agonism for lean mass improvement.
- Veldhuis et al. (2005) — JCEM: Dual GHRH + GHS stimulation produces 2-3x greater GH release than either alone, confirming synergistic mechanism.
Research Applications
- Pulsatile GH secretion pattern studies
- GH-IGF-1 axis research
- Body composition and lean mass investigation
- Sleep architecture and GH release studies
- Recovery and tissue repair research
- Aging-related GH decline (somatopause) modeling
Chemical Properties
- CJC-1295 (No DAC): Modified GRF (1-29), MW: 3367.97 g/mol. Also known as Mod GRF 1-29 or Tetrasubstituted GRF 1-29.
- Ipamorelin: Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), MW: 711.85 g/mol, CAS: 170851-70-4
- Blend ratio: 5mg CJC-1295 + 5mg Ipamorelin per 10mg vial
- Appearance: White lyophilized powder
- Storage: -20°C lyophilized; 2-8°C reconstituted
Related product: CJC-1295 + Ipamorelin (No DAC) — Janoshik-tested, COA included, research use only.
Disclaimer: This information is compiled from published peer-reviewed research for educational purposes only. Grey Research compounds are intended for in vitro research and laboratory use only. Not for human consumption.
Certificate of Analysis
Independent third-party HPLC lab test by Janoshik Analytical. Every batch is tested before release.
Click to view full-size lab report.